Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid

Peking University

Status: Completed

Conditions: Bullous Pemphigoid

Treatments: Drug: Dupilumab

Study type: Observational

Funder types: Other

Identifiers

NCT05649579

2022Y446

Details and patient eligibility

About

This study was designed to be a retrospective, multicentre, observational study to evaluate the efficacy and safety of dupilumab in the treatment of bullous pemphigoid and to find predictors of efficacy.

Enrollment: 146 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult bullous pemphigoid patients treated with dupilumab between January 1, 2021, and July 31, 2022, at six leading dermatology departments in the Chinese Collaborative Network for Autoimmune Bullous Diseases.
• The diagnosis of BP requires clinical manifestations and immunological or pathological evidences.
• Dupilumab treatment should continue for at least 4 weeks and possibly longer.

Exclusion criteria

• Drug-induced BP, γ-1 pemphigoid
• Patients with less than 4 weeks of follow-up
• Patients were given any other biologicals within 6 months before the first dupilumab administration